Evidence map›Paper›PMID 33776334›Full record

ArticleUrology annals

Magnetic resonance imaging-ultrasound fusion-targeted biopsy combined with systematic 12-core ultrasound-guided biopsy improves the detection of clinically significant prostate cancer: Are we ready to abandon the systematic approach?

Christopher Antonio Febres-Aldana, Sarah Alghamdi, Thomas A Weppelmann, Emilio Lastarria, Akshay Bhandari, Yumna Omarzai, Robert J Poppiti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology annals. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Christopher Antonio Febres-AldanaArkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Florida, USA.
Sarah AlghamdiArkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Florida, USA.
Thomas A WeppelmannDepartment of Pathology, Herbert Wertheim College of Medicine, Florida International University, Florida, USA.
Emilio LastarriaColumbia University Division of Urology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
Akshay BhandariColumbia University Division of Urology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
Yumna OmarzaiArkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Florida, USA.
Robert J PoppitiArkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Florida, USA.
Mount Sinai Medical Center · USFlorida International University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiparametric (mp) magnetic resonance imaging (MRI)-ultrasound fusion-targeted biopsy (TB) has improved the detection of clinically significant prostate cancer (csCaP) using the Prostate Imaging Reporting and Data System (PI-RADS) reporting system, leading some authors to conclude that TB can replace the 12-core systematic biopsy (SB). We compared the diagnostic performance of TB with SB at our institution.

methodsEighty-three men with elevated prostate-specific antigen levels (6.6 ng/mL, interquartile range [IQR] 4.5-9.2) and abnormal mp-MRI (127 lesions, PI-RADS ≥3, median size: 1.1 cm, IQR 0.8-1.6) underwent simultaneous TB and SB. Diagnosis of any CaP (Gleason score, [GS] ≥6) and csCaP (GS ≥7) was compared using the McNemar's exact test.

resultsSB showed higher, but not statistically significant, detection rates of any CaP and csCaP (51.8% and 34.9%) versus TB (44.6% and 28.9%) (

conclusionA combination of SB with TB remained necessary for achieving the highest cancer detection rates. Limiting prostate biopsy to TB alone can miss csCaP due to the presence of synchronous high-grade cancer invisible on MRI or failure to hit the target. TB is the best approach for anterior lesions and tumor quantification.

Indexed as

Cancer detectionfusion targeted biopsymultiparametric magnetic resonance imagingprostate biopsyprostate cancer

Identifiers

PMID33776334
PMCPMC7992529
OpenAlexW3092679749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.